General Information of Drug (ID: DMCHPMA)

Drug Name
SNAP-8719 Drug Info
Synonyms
CHEMBL98241; SNAP-8719; SCHEMBL6753278; WCWNYVYNQAPOOX-OAHLLOKOSA-N; BDBM50122803; 8-{(1R)-2-[4-(2,4,5-Trifluorophenyl)piperazin-1-yl]-1-methylethyl}-8-azaspiro[4.5]decane-7,9-dione; 8-{1-Methyl-2-[4-(2,4,5-trifluoro-phenyl)-piperazin-1-yl]-ethyl}-8-aza-spiro[4.5]decane-7,9-dione; 8-{(R)-1-Methyl-2-[4-(2,4,5-trifluoro-phenyl)-piperazin-1-yl]-ethyl}-8-aza-spiro[4.5]decane-7,9-dione
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9845181
TTD Drug ID
DMCHPMA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methamphetamine DMPM4SK Anxiety Approved [2]
Propericiazine DME9JNL Psychiatric disorder 6E8Z Approved [3]
Methoxamine DMF5XQH Hypertension BA00-BA04 Approved [4]
Phendimetrazine DM6TS1N Obesity 5B81 Approved [5]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [6]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [7]
Sunepitron DM6M8ZX N. A. N. A. Discontinued in Phase 3 [8]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [9]
SOU-001 DMPAEK5 Urinary incontinence MF50.2 Discontinued in Phase 2 [10]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxazosin DM9PLRH Benign prostatic hyperplasia GA90 Approved [12]
Armodafinil DMGB035 Malignant glioma 2A00.0 Approved [13]
Alfuzosin DMZVMKF Benign prostatic hyperplasia GA90 Approved [14]
Moxisylyte DMFCLYW Erectile dysfunction HA01.1 Approved [15]
Terazosin DM3JCVS Benign prostatic hyperplasia GA90 Approved [16]
Bunazosin DM4I8O7 Glaucoma/ocular hypertension 9C61 Approved [17]
Trimazosin DM1QLST Congestive heart failure BD10 Approved [18]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [6]
DL-017 DMM8GZT Hypertension BA00-BA04 Phase 1 [19]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting 5-HT 1A receptor (HTR1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [21]
Buspirone DMBS632 Anxiety disorder 6B00-6B0Z Approved [22]
OPC-34712 DMHG57U Major depressive disorder 6A70.3 Approved [23]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [24]
Flibanserin DM70DTN Depression 6A70-6A7Z Approved [25]
Gepirone DMGX5Q0 Major depressive disorder 6A70.3 Approved [26]
TERTATOLOL DM2L3D5 Hypertension BA00-BA04 Approved [27]
Urapidil DMD59GI Hypertension BA00-BA04 Approved [28]
Treximet DMU54QB Migraine 8A80 Approved [29]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [30]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [31]
NAFTOPIDIL DMQ8R4E Hypertension BA00-BA04 Approved [31]
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [21]
Xatral DMLHOA0 Benign prostatic hyperplasia GA90 Approved [32]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [29]
Besipirdine DMLVNTA Cognitive impairment 6D71 Phase 3 [33]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [6]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [20]
PMID30124346-Compound-LDT66 DMJMTNL Benign prostatic hyperplasia GA90 Patented [20]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1A (ADRA1A) TTNGILX ADA1A_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1B (ADRA1B) TTBRKXS ADA1B_HUMAN Inhibitor [1]
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Inhibitor [1]

References

1 Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9.
2 Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9.
3 Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91.
4 Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2.
5 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
6 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
7 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
8 An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35.
9 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
10 Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.
11 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
12 The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
13 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
14 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
15 Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
16 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
17 Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
18 The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
19 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
20 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
21 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
22 Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
23 Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
24 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
25 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
26 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
27 Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
28 Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
29 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
30 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
31 Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
32 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
33 Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.